Media Pack
News

Current Edition

Volume 16 issue 2
 
 
 
 
 
 
Volume 16 Issue 2

PCI Discusses Annex 1 Complaint Expansion Plans for Sterile Fill-Finish and Lyophilization 

In 2022 PCI Announced a $100 Million Investment into Expanding Its Sterile Fill-Finish Service Offering – Can You Provide an Update on How This is Progressing?    ...
8 July 2024 Volume 16 Issue 2 | Current Features
Continue Reading →
Volume 16 Issue 2

AI & Automation: How Advanced is Adoption in Life Sciences R&D?  

Forward-thinking life sciences organisations have switched on to the benefits of AI-powered automation, to transform their research and development operations and st...
8 July 2024 Volume 16 Issue 2 | Current Features Artificial Intelligence | blockchain
Continue Reading →
Volume 16 Issue 2

Alleviating Regulatory Burden Through Access Consortium 

While regulatory authorities are in- creasingly adopting reliance programs to assess applications, few offer the opportunity to take advantage of simultaneous assess...
8 July 2024 Volume 16 Issue 2 | Current Features COVID-19 | healthcare
Continue Reading →
Volume 16 Issue 2

Integrating Medical Devices into Pharmacovigilance Portfolios   

How to Navigate the Latest EU Medical Device Regulatory Landscape to Successfully Adapt your Pharma Portfolio Understanding medical device regulations is essentia...
8 July 2024 Volume 16 Issue 2 | Current Features development | drug
Continue Reading →
Volume 16 Issue 2

The Oncology Crux – Asking the Smart Oncology Questions Before Shaping an Asset’s Journey to Market   

With over 2,000 oncology clinical trials currently ongoing, the speed at which the market is evolving makes it increasingly difficult for pharmaceutical companies to...
8 July 2024 Volume 16 Issue 2 | Current Features
Continue Reading →
Volume 16 Issue 2

Engaging Minority Communities: Collaborative Practises and Long-Term Success  

The quest to understand and treat rare diseases poses unique challenges. Rare diseases, often referred to as orphan diseases, affect a small percentage of the popula...
8 July 2024 Volume 16 Issue 2 | Current Features development | healthcare
Continue Reading →
Volume 16 Issue 2

The Importance of Polymorph Screenings: Risk Mitigation and Manufacturing Control   

Polymorphism in pharmaceuticals may affect drug product (DP) development, clinical studies, manufacturing, quality and stability. Therefore, it is mandatory to gain ...
8 July 2024 Volume 16 Issue 2 | Current Features
Continue Reading →
Volume 16 Issue 2

Why X-ray Inspection is a Viable Quality Assurance Solution for Pharma Products 

We are all aware that the pharmaceutical industry operates within a highly regulated environment, where upholding product safety and quality is paramount. Manufactur...
8 July 2024 Volume 16 Issue 2 | Current Features development | healthcare
Continue Reading →
Volume 16 Issue 2

Adaptive, Innovative and Future-Ready: How CDMOs are Staying Sharp 

As the pharma and biotech sector navigates economic uncertainties and evolving customer demands, the contract development and manufacturing industry is undergoing a ...
8 July 2024 Volume 16 Issue 2 | Current Features development | healthcare
Continue Reading →
Volume 16 Issue 2

Child Resistant Closures: Exploring New Paths Between Safety and Accessibility   

In the intricate and highly regulated landscape of the pharmaceutical industry, patient safety is an aspect that unequivocally stands out in its importance. A corner...
8 July 2024 Volume 16 Issue 2 | Current Features Child-Resistant Packaging | children's safety
Continue Reading →
 
 
logo-ipi-w.png

International Pharmaceutical Industry

IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative

Facebook Linkedin Tumblr
IPI Media © 2024, All Rights Reserved – Powered by Teksyte